

Global COVID-19 Clinical Platform RAPID CORE CASE REPORT FORM (CRF)

INTRODUCTION

In response to the COVID-19 pandemic, the World Health Organization (WHO) has launched a global COVID-19 anonymized clinical data platform (the "COVID-19 Data Platform") to enable State Parties to the International Health Regulations (IHR) (2005) to share with WHO anonymized clinical data related to patients with suspected or confirmed infections with SARS-CoV-2 (collectively "anonymized COVID-19 data"). The anonymized COVID-19 data received by WHO will remain the property of the contributing Entity and will be used by WHO for purposes of verification, assessment and assistance pursuant to the IHR (2005), including to inform the public health and clinical operation response in connection with the COVID-19 outbreak. To help achieve these objectives, WHO has established an independent Clinical Advisory Group to advise WHO on global reporting and analysis of the anonymized clinical COVID-19 data. State Parties and other entities are invited to contact WHO to obtain more information about how to contribute anonymized clinical COVID-19 data to the WHO Data Platform. To preserve the security and confidentiality of the anonymized COVID-19 data, State Parties and other entities are respectfully requested to take all necessary measures to protect their respective log-in credentials and passwords to the COVID-19 Data Platform.

The anonymized COVID-19 data will be stored in the WHO COVID-19 Data Platform, which is a secured, access-limited, password protected electronic platform. WHO will (i) protect the confidentiality and prevent the unauthorized disclosure of the anonymized COVID-19 data; (ii) implement and maintain appropriate technical and organizational security measures to protect the security of the anonymized COVID-19 data and the COVID-19 Data Platform. In accordance with Article 11(4) of the IHR (2005), WHO will not make the anonymized COVID-19 data generally available to other State Parties or entities until such time as any of the conditions set forth in paragraph 2 of Article 11 are first met, and following consultation with affected countries/entities. Pursuant to that same Article 11, WHO will not make the anonymized COVID-19 data available to the public, unless and until the anonymized COVID-19 data have already been made available to State Parties, and provided that other information about the COVID-19 epidemic has already become publicly available and there is a need for the dissemination of authoritative and independent information. To contribute data to the WHO COVID-19 Data Platform or to receive more information, please contact:

DESIGN OF THIS CASE REPORT FORM (CRF)

The Rapid Core CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected prospectively or retrospectively. The data collection period is defined as the period from hospital admission to discharge, transfer, death, or continued hospitalization without possibility of continued data collection.

This CRF has 3 modules:

Module 1: to be completed on the first day of admission to the health centre.

Module 2: to be completed daily during hospital stay for as many days as resources allow.

Continue to follow-up patients who transfer between wards.

Module 3: to be completed at discharge or death.

GENERAL GUIDANCE

- Participant identification numbers consist of a site code and a participant number. You can register
 on the data management system by contacting COVID_ClinPlatform@who.int, and our data
 management team will contact you with instructions for data entry and will assign you a 5-digit site
 code at that time.
- Please contact us at COVID ClinPlatform@who.int for any information.

MODULE 1. Complete on hospital admission (within 24 hrs from hospital admission)

Facility name	Country								
Date of enrolment [D] [D]/ [M] [M]/ [2] [0] [Y]	Y								
1a. CLINICAL INCLUSION CRITERIA									
One or more A history of self-reported feveris	hness or measured fever of ≥38°C	□Yes □No							
of these Cough		□Yes □No							
during this Dyspnoea (shortness of breath)	Dyspnoea (shortness of breath) OR Tachypnoea* □Yes □No								
illness Clinical suspicion despite not me	eeting criteria above	□Yes □No							
* Respiratory rate ≥ 50 breaths/min for < 1 year; ≥ 40 for 1–4 ye	•	/ears							
4L DEMOCRABILION	41- DEMOCRAPHICO								
1b. DEMOGRAPHICS Sex at birth □Male □Female □Not specified Date of bi	rth [D][D]/[M][M]/[Y][Y	/ 1 / 1 / 1							
If date of birth is unknown, record: Age [][] ye									
Health care worker? □Yes □No □Unknown Labo									
Pregnant?* □Yes □No □Unknown □N/A If yes	s: Gestational weeks assessmen	t [][]weeks							
If currently pregnant or recently pregnant (delivery within 2									
1c. DATE OF ONSET AND ADMISSION VITAL SIGNS (fin	•	•							
Symptom onset (date of first/earliest symptom) [D][D									
Admission date at this facility D_DD/LM_N_M_/L									
Temperature [][].[]°C Heart rate [_][][_ Jbeats/min								
Respiratory rate [][]breaths/min									
BP [] [](systolic) [][](diastolic) mr	nHg Severe dehydration □Yes	□No □Unknown							
Sternal capillary refill time > 2 seconds □Yes □No □	lUnknown								
Oxygen saturation: [][]% on □Room air □Oxyg	en therapy □Unknown	/ P U (circle one)							
Glasgow Coma Score (GCS/15) [][] Mair	nutrition □Yes □No □Unknown								
Mid-upper arm circumference [][][]mm	leight [] []cm W	eight [][]kg							
1d. CO-MORBIDITIES (existing at admission) (Unk = Unk	,								
Chronic cardiac disease ☐Yes ☐No ☐Unk (not hypertension)	Diabetes 🔲	∕es □No □Unk							
Hypertension □Yes □No □Unk	Current smoking	res □No □Unk							
Chronic pulmonary disease □Yes □No □Unk	Tuberculosis (active)	res □No □Unk							
Asthma	Tuberculosis (previous)	res □No □Unk							
Chronic kidney disease □Yes □No □Unk	Asplenia 🔲	res □No □Unk							
Chronic liver disease □Yes □No □Unk	Malignant neoplasm □\	res □No □Unk							
Chronic neurological disorder □Yes □No □Unk	Other	∕es □No □Unk							
	If yes, specify:								
HIV □Yes (on ART) □Yes	(not on ART) □No □Unknown	ART regimen							
1e. PRE-ADMISSION AND CHRONIC MEDICATION We	ere any of the following taken wit	hin 14 days of admission							
Angiotensin converting enzyme inhibitors (ACE inhibitors)		-							
Angiotensin II receptor blockers (ARBs)?	□Yes □No □Unknown								
Non-steroidal anti-inflammatory (NSAID)?	□Yes □No □Unknown								
Antiviral? □Chloroquine/hydroxychloroquine □Azithromycin □Lopinavir/Ritonavir □Other:									



ARTICIPANT ID I	1.1	1.1	- 1.1	1.1	1 1	- 1.1	1.1	1.1	- 1
ANTICIPAINT ID I	11	11	11	11	1 1	11	11	11	- 1

1f. SIGNS AND SYMPTOMS C	N ADMISSION (Unk =	Unknown)	
History of fever	□Yes □No □Unk	Lower chest indrawing	□Yes □No □Unk
Cough	□Yes □No □Unk	Headache	□Yes □No □Unk
with sputum production	□Yes □No □Unk	Altered consciousness/confusion	□Yes □No □Unk
with haemoptysis	□Yes □No □Unk	Seizures	□Yes □No □Unk
Sore throat	□Yes □No □Unk	Abdominal pain	□Yes □No □Unk
Runny nose	□Yes □No □Unk	Vomiting/nausea	□Yes □No □Unk
Wheezing	□Yes □No □Unk	Diarrhoea	□Yes □No □Unk
Chest pain	□Yes □No □Unk	Conjunctivitis	□Yes □No □Unk
Muscle aches	□Yes □No □Unk	Skin rash	□Yes □No □Unk
Joint pain (arthralgia)	□Yes □No □Unk	Skin ulcers	□Yes □No □Unk
Fatigue/malaise	□Yes □No □Unk	Lymphadenopathy	□Yes □No □Unk
Loss of taste	□Yes □No □Unk	Inability to walk	□Yes □No □Unk
Loss of smell	□Yes □No □Unk	Bleeding	□Yes □No □Unk
Shortness of breath	□Yes □No □Unk	If bleeding, specify site(s):	
Stroke: ischaemic stroke			
Stroke: intracerebral haemorrh	age □Yes □No □U	Ink	
Other:	□Yes □No □Unk		
If yes, specify:			
,,			
1a. MEDICATION On the	day of admission, did t	he patient receive any of the follow	vina:
		Intravenous fluids? □Yes □No □	
_		n □Lopinavir/Ritonavir □Neuramini	
	-	fy:	
·	•	•	
Corticosteroid?	·	ıte: □Oral □Intravenous □Inhaled se:	
Antibiotic? □Yes □No □Un	-		
Antifungal agent? □Yes □N			
Antimalarial agent?		enocify:	
	•	· · · · · · · · · · · · · · · · · · ·	
Experimental agent?	•	· · · ·	
Non-steroidal anti-inflammato	,		
	•	ibitors) □Yes □No □Unknown	
Angiotensin II receptor block	ers (ARBs) □Yes □No	□ Unknown	
Systemic anticoagulation □Y	es □No □Unknown		
// AUDDODEN/E ALDE			
	•	on, did the patient receive any of th	ie following:
ICU or high dependency unit Oxygen therapy? □Yes □Ne			
Oxygen therapy? \Box res \Box No. \bigcirc flow: \Box 1–5 L/min \Box 6–1	•	•	
Source of oxygen: □Piped			
	•	ask □Mask with reservoir □CPAP/	NIV mask ⊟Unknown
Non-invasive ventilation? (e.g			THE MIGHT EDITION
Invasive ventilation (any)?	•		
If yes, what were the follow			
	ving values closest to	08:00:	
,	_		'aO2
Extracorporeal (ECMO) suppo	(%); Plateau pres	sure (cm H ₂ O); PaCO ₂ ; P	°aO ₂
Extracorporeal (ECMO) support Prone position?	(%); Plateau pres	sure (cm H ₂ O); PaCO ₂ ; F known	⁹ aO ₂



ARTICIPANT ID	I II	11 11	11 1		11 11	I	Module 1 – page 3

1i. LABORATORY RESULTS ON ADMISSION (*record units if different from those listed)									
Parameter	Value*		Units		Parameter	Value*	ι	Units	
Haemoglobin		□ g/L	□ g/dL		Creatinine		□ mg/L	□ µmol/L	
WBC count		□ /mm³	☐ G/L (= x10 ⁹ /L)		Sodium		□ mEq.	/L = mmol/L	
Haematocrit			%		Potassium		□ mEq.	/L = mmol/L	
Platelets		□ /mm³	☐ G/L (= x10 ⁹ /L)		Procalcitonin		□ ng/mL	□ µg/L	
APTT/APTR		☐ seconds			CRP		☐ mg/L		
PT (seconds)		☐ seconds			LDH		□ IU/L		
INR					Creatine kinase		□ IU/L	□ UKAT/L	
ALT/SGPT			□ IU/L		Troponin		□ ng/mL □ μg/L		
AST/SGOT		□ IU/L			ESR		□mm/hour		
Total bilirubin		☐ mg/L	□ µmol/L		D-dimer		□ ng/mL	□ µg/L	
Urea (BUN)		□ g/L	□ mg/dL	□ mmol/L	Ferritin		□ ng/mL	□ µg/L	
Lactate		☐ mg/dL	□ mmol/L		IL-6			pg/mL	

MODULE 2. Daily follow up during hospital stay (daily or as frequent as possible based on feasibility)

Date of follow up [D][D]/[M][M]/[2][0][Y][Y]

2a. VITAL SIGNS (record m	nost abnormal value bet	ween 00:00 to 24:00)						
Temperature [].[].	Temperature [][].[]°C Heart rate [][]beats per min Respiratory rate [][]breaths/min							
BP [] [] (systolic)) [][][](diastol	ic)mmHg Severe dehydration □Ye	es □No □Unknown					
Sternal capillary refill time	> 2 seconds □Yes □	□No □Unknown A	V P U (circle one)					
Oxygen saturation	on □Room air □Oxyç	en therapy □Unknown GCS/15 [_]	[
2b. DAILY CLINICAL FEAT	URES (Unk = Unknown)						
Cough	□Yes □No □Unk	Confusion	□Yes □No □Unk					
and sputum production	□Yes □No □Unk	Seizures	□Yes □No □Unk					
Sore throat	□Yes □No □Unk	Vomiting/nausea	□Yes □No □Unk					
Chest pain	□Yes □No □Unk	Diarrhoea	□Yes □No □Unk					
Shortness of breath	□Yes □No □Unk	Conjunctivitis	□Yes □No □Unk					
Loss of smell	□Yes □No □Unk	Myalgia	□Yes □No □Unk					
Loss of taste	□Yes □No □Unk	Other, specify:	□Yes □No □Unk					
			1 1 1 2 2 1 1 4 0 1 1 K					
2c. LABORATORY RESUL	TS (*record units if diffe	rent from those listed)						

2c. LABORATORY RESULTS (*record units if different from those listed)											
Parameter	Value*	Units			Parameter	Value*	Uı	nits			
Haemoglobin		g/L	g/dL		Creatinine		mg/L	µmol/L			
WBC count		/mm³	G/L (= x10 ⁹ /L)		Sodium		mEq/L	= mmol/L			
Haematocrit		%			Potassium		mEq/L = mmol/L				
Platelets		/mm³	G/L (= x10 ⁹ /L)		Procalcitonin		ng/mL	μg/L			
APTT/APTR		seconds			CRP		mg/L				
PT (seconds)		seconds			LDH		IU/L				
INR					Creatine kinase		IU/L	UKAT/L			
ALT/SGPT		1	IU/L		Troponin		ng/mL	μg/L			
AST/SGOT		IU/L		IU/L			ESR		mm/hour		
Total bilirubin		mg/L	µmol/L		D-dimer		ng/mL	µg/L			
Urea (BUN)		g/L	mg/dL	 mmol/L	Ferritin		ng/mL	μg/L			
Lactate		mg/dL	mmol/L		IL-6		pg	ı/mL			



Organization PARTICIPANT ID I II
2d. MEDICATION At any time during this 24-hour hospital day, did the patient receive:
Oral/orogastric fluids? □Yes □No □Unknown Intravenous fluids? □Yes □No □Unknown
Antiviral? □Yes □No □Unknown If yes: □Ribavirin □Lopinavir/Ritonavir □Neuraminidase inhibitor
□Interferon alpha □Interferon beta □Other, specify:
Corticosteroid? □Yes □No □Unknown If yes, route: □Oral □Intravenous □Inhaled
If yes, please provide agent and maximum daily dose:
Antibiotic? Yes No Unknown If yes, specify:
Antifungal agent? □Yes □No □Unknown
Antimalarial agent? Yes No Unknown If yes, specify:
Experimental agent? Yes No Unknown If yes, specify:
Non-steroidal anti-inflammatory (NSAID) □Yes □No □Unknown
Angiotensin converting enzyme inhibitors (ACE inhibitors) □Yes □No □Unknown
Angiotensin II receptor blockers (ARBs) □Yes □No □Unknown
Systemic anticoagulation □Yes □No □ Unknown
2e. SUPPORTIVE CARE At any time during this 24-hour hospital day, did the patient receive:
ICU or high dependency unit admission? □Yes □No □Unknown
Date of ICU/HDU admission [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □Unknown
ICU/HDU discharge date <code>_D_][D_]/[M_][M_]/[2_][0_][Y_][Y_]</code> □Not discharged yet □Unknown
Oxygen therapy? □Yes □No □Unknown If yes, complete all below:
O ₂ flow: □1–5 L/min □6–10 L/min □11–15 L/min □ > 15 L/min □Unknown
Source of oxygen: □Piped □Cylinder □Concentrator □Unknown

Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask □Unknown

PEEP (cm H_2O) ; FiO_2 (%) ; $PaCO_2$; $PaCO_2$; $PaCO_2$

Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □Unknown

Renal replacement therapy (RRT) or dialysis?

Yes

No

Unknown

If yes, what were the following values closest to 08:00:

Extracorporeal (ECMO) support?

Yes

No

Unknown

Invasive ventilation (any)? □Yes □No □Unknown

Inotropes/vasopressors? □Yes □No □Unknown

Prone position? □Yes □No □Unknown



PARTICIPANT ID I	1 1	1 1	1 1	I I	I II	- 11	Π	

MODULE 3. Complete at discharge/death

3a. DIAGNOSTIC/PATHOGEN TES	TING		
Chest X-ray/CT performed? □Yes	□No □Unknown If yes ,	infiltrates present? □\	′es □No □Unknown
Was pathogen testing done during	g this illness episode? □Ye	s □No □Unknown If	yes , complete all below:
Influenza virus: □Positive □Ne	gative □Not done	If positive, type	
Coronavirus: □Positive □Negat	ive □Not done If positive: □	IMERS-CoV DSARS-Co	oV-2 □Other
Other respiratory pathogen: 🔲			
Viral haemorrhagic fever: □Pos	=		irus
Other pathogen of public healt	•	es, specify:	<u> </u>
Falciparum malaria: □Positive			
Non-falciparum malaria: □Posi			
HIV: □Positive □Negative □No	<u>-</u>		
niv. Drositive Divegative Divo	t done		
3b. COMPLICATIONS At any time	e during hospitalization, did	d the patient experience) :
Shock	□Yes □No □Unknown	Bacteraemia	□Yes □No □Unknown
Seizure	□Yes □No □Unknown	Bleeding	□Yes □No □Unknown
Meningitis/encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown
Anaemia	□Yes □No □Unknown	Myocarditis/pericarditis	
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown
Preumonia Prepobiolitie	☐Yes ☐No ☐Unknown☐Yes ☐No ☐Unknown	Liver dysfunction	□Yes □No □Unknown
Bronchiolitis Acute respiratory distress syndrome	Lifes Lino Lonknown	Cardiomyopathy Other	□Yes □No □Unknown
(ARDS)	□Yes □No □Unknown	If yes, specify	□Yes □No □Unknown
Stroke: ischaemic stroke	□Yes □No □Unknown		
Stroke: intracerebral haemorrhage	□Yes □No □Unknown		
3c. MEDICATION While hospitalize	zed or at discharge, were ar	ny of the following admi	nistered:
Oral/orogastric fluids? □Yes □No	□Unknown Intravenous f	luids? □Yes □No □Un	known
Antiviral? □Yes □No □Unknown	If yes: □Ribavirin □Lopin	avir/Ritonavir □Neurami	nidase inhibitor
□Interferon alpha □Interferon b	eta □Other, specify:		
Corticosteroid? □Yes □No □Un	known If ves. route: □Oral	□Intravenous □Inhaled	
If yes, specify agent and maxim	_		
Antibiotic? □Yes □No □Unknow	· —	<u>_</u>	
Antifungal agent? □Yes □No □l	Jnknown If yes, specify: _		
Antimalarial agent? □Yes □No □	□Unknown If yes , specify:_		
Experimental agent? □Yes □No			
Non-steroidal anti-inflammatory (N	SAID) □Yes □No □Unkr	nown If yes , specify:	
Systemic anticoagulation □Yes □			



3d. SUPPORTIVE CARE At any time during hospitalization, did the patient receive/undergo:
ICU or high dependency unit admission? □Yes □No □Unknown If yes, total duration:days
Date of ICU admission [D][D]/[M][M]/[2][0][Y][Y] □N/A
Date of ICU discharge <code>_D_][D_]/[M_][M_]/[2_][0_][Y_][Y_]</code> □In ICU at outcome □N/A
Oxygen therapy? Yes No Unknown If yes, complete all: Total duration:days
O₂ flow: □1–5 L/min □6–10 L/min □11–15 L/min □ > 15 L/min
Source of oxygen: □Piped □Cylinder □Concentrator
Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask
Non-invasive ventilation? (e.g. BIPAP, CPAP) Yes No Unknown If yes, total duration: days
Invasive ventilation (any)? □Yes □No □Unknown If yes, total duration:days
Extracorporeal (ECMO) support? Yes No Unknown If yes, total duration: days
Prone position? □Yes □No □Unknown If yes, total duration:days
Inotropes/vasopressors? □Yes □No □Unknown If yes, total duration:days
Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown
3e. OUTCOME
Outcome: □Discharged alive □Hospitalized □Transfer to other facility □Death □Palliative discharge □Unknown

If discharged alive, ability to self-care at discharge versus before illness:

Same as before illness:

Worse

Outcome date: $\[\] \[\] \[\]$

PARTICIPANT ID I ___ | I ___ |

Module 3 – page 7

□Better □Unknown